DARPA Awards up to $10.7 Million Contract to RxMP Therapeutics, Inc.
Award will support completion of IND-enabling development and manufacturing scale-up of RMP-402 under DARPA's RAPIID program SEATTLE, Oct. 20, 2026 /PRNewswire/ -- RxMP Therapeutics, Inc. ("RxMP"), a late pre-clinical stage therapeutics company developing novel therapies for the rapid...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.